Abstract: The invention includes isolated nucleic acid molecules encoding a Rhesus ob gene product that regulates obesity in mammals. A preferred embodiment consisting of a native DNA sequence is disclosed, as are vectors and methods for expressing the Rhesus ob gene product.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: The invention discloses modified forms of the enzyme tissue plasminogen activator (t-PA) in which recombinant DNA techniques are utilized to modify the structure of the t-PA cDNA to express a modified t-PA which retains the ability to activate plasminogen yet binds less efficiently to plasmin inhibitor. The invention provides novel DNA compounds and recombinant DNA expression vectors that encode modified human t-PA wherein all or a portion of the kringle protein domains of native human t-PA are removed. Both eukaryotic and prokaryotic expression vectors containing the modified t-PA DNA have been constructed and used to transform Chinese hamster ovary cells and Escherichia coli cells.

Abstract: The present invention is composed of novel recombinant DNA expression vectors which contain a transcriptional activating sequence, a translational activating sequence and a DNA sequence coding for a functional polypeptide, especially bovine growth hormone. The aforementioned translational activating sequences contain a ribosome binding site and are designed to provide high level expression of DNA that codes for virtually any functional polypeptide. The invention further provides transformed microbial host cells capable of producing bovine growth hormone and other functional polypeptides at high levels.

Abstract: The present invention provides a method for transforming an actinomycete with an integrating vector which has the advantages of high transformation rates into a broad host range, site-specific integration, and stable maintenance without antibiotic selection. Also provided are methods for the increased production of antibiotics and for the production of hybrid antibiotics.

Abstract: The carE gene of Streptomyces thermotolerans has been isolated and used to construct recombinant DNA expression vectors. The carE gene encodes 4"-O-isovaleryl acylase activity important in the biosynthesis of a number of useful antibiotics. The carE gene can be used not only to construct recombinant cells with an increased ability to produce the acylase enzyme but also to construct recombinant cells with the ability to produce novel antibiotic compounds.

Abstract: The present invention is composed of novel recombinant DNA expression vectors which contain a transcriptional activating sequence, a translational activating sequence and a DNA sequence coding for a functional polypeptide, especially bovine growth hormone. The aforementioned translational activating sequences contain a ribosome binding site and are designed to provide high level expression of DNA that codes for virtually any functional polypeptide. The invention further provides transformed microbial host cells capable of producing bovine growth hormone and other functional polypeptides at high levels.

Abstract: The carG gene of Streptomyces thermotolerans has been isolated and used to construct recombinant DNA expression vectors. The carG gene encodes the activities required for the biosynthesis of the 16-member cyclic lactone of carbomycin. The carG gene can be used not only to construct recombinant cells with an increased ability to produce carbomycin but also to construct recombinant cells with the ability to produce novel antibiotic compounds.

Abstract: The carB gene is a novel carbomycin resistance-conferring gene isolated from Streptomyces thermotolerans and used to construct a number of cloning vectors for use in Streptomyces and related organisms. One such coloning vector, plasmid pOJ159, can be obtained in S. griseofuscus C581 under the accession number NRRL 18090. S. lividans and S. griseofuscus are the preferred hosts when the carB gene is used to select carbomycin-resistant Streptomyces transformants.

Abstract: The carA gene is a novel carbomycin resistance-conferring gene isolated from Streptomyces thermotolerans and used to construct a number of cloning vectors for use in Streptomyces and related organisms. One such cloning vector, plasmid pOJ158, can be obtained in S. griseofuscus C581 under the accession number NRRL 18089. S. lividans and S. griseofuscus are the preferred hosts when the carA gene is used to select carbomycin-resistant Streptomyces transformants.

Abstract: The present invention comprises improved derivatives of the tryptophan operon useful for expressing fused gene products in E. coli and relate organism. Two of the improved derivatives disclosed are encoded on 0.43 and 0.55 kb EcoRI restriction fragments from plasmids pCZ20 and pLEBGH2 (in strains NRRL B-15881 and NRRL B-15882), respectively. The modified derivatives have been placed on recombinant DNA cloning and expression vectors. A variety of expression vectors have been constructed that drive expression of fused gene products. Two novel gene sequences, encoding insulin-like growth factors I and II, have been expressed with the modified tryptophan operon system.